HemaSphere (Jun 2022)

S200: IMPROVED OVERALL SURVIVAL WITH FIRST-LINE BRENTUXIMAB VEDOTIN PLUS CHEMOTHERAPY IN PATIENTS WITH STAGE III/IV CLASSICAL HODGKIN LYMPHOMA: 6-YEAR ANALYSIS OF ECHELON-1

  • M. Hutchings,
  • S. M. Ansell,
  • D. J. Straus,
  • J. M. Connors,
  • W. S. Kim,
  • A. Gallamini,
  • R. Ramchandren,
  • J. W. Friedberg,
  • R. Advani,
  • A. M. Evens,
  • P. Smolewski,
  • K. J. Savage,
  • N. L. Bartlett,
  • H.-S. Eom,
  • J. S. Abramson,
  • C. Dong,
  • F. Campana,
  • K. Fenton,
  • M. Puhlmann,
  • J. Radford

DOI
https://doi.org/10.1097/01.HS9.0000843692.94815.d7
Journal volume & issue
Vol. 6
pp. 101 – 102

Abstract

Read online

No abstracts available.